Dementia with Lewy Bodies

Lewy body disease care addresses both motor and cognitive symptoms with major diagnostic advances. The session covers alpha-synuclein seed amplification assays (SAA, RT-QuIC) as a diagnostic biomarker, cognitive fluctuations management, REM sleep behaviour disorder (RBD) as the strongest prodromal predictor, neuropsychiatric symptoms including hallucinations and Capgras phenomenon, the antipsychotic-sensitivity warning (avoid typical neuroleptics, cautious with atypicals, pimavanserin as alternative), and disease-modifying trials targeting alpha-synuclein. Discussion addresses visual hallucination management with rivastigmine and pimavanserin, autonomic features and management, the comparison of DLB vs PD-D vs AD diagnostic features, the staging biological definition under proposed criteria, and emerging biomarkers for early diagnosis.